Agenus Provides Corporate Update and First Quarter 2023 Fina

At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median... | May 9, 2023

Related Keywords

United States , New York , Barcelona , Comunidad Autonoma De Cataluna , Spain , Chicago , Illinois , American , Garo Armen , Agenus Inc , Society Of Gynecologic Oncology , Twitter , Nasdaq , American Society Of Clinical Oncology , World Congress On Gastrointestinal Cancer , Exchange Commission , Chief Executive Officer , American Society , Clinical Oncology , Gastrointestinal Cancers Symposium , Gynecologic Oncology , Fast Track Designation , Gastrointestinal Cancer , Combination With , First Line Treatment , Patients With , Metastatic Squamous Cell Carcinoma , Combination Therapy , With Advanced Solid Tumors , Risk Factors , Quarterly Report , Annual Report , Agenus Inc Stock Exchange , News , Information , Press Release , It , Presentation , Combination , Remonstrated , Verall , Survival , Gate , N , Metastatic , Olorectal , Dancer , Patients , Who , Wave , Ailed Agen Us00847g7051 ,